Rocket Pharmaceuticals Reports $50.3 Million Net Loss in Q3 2025, Reduces Operating Expenses

Rocket Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $50.3 million, a decrease from a net loss of $66.7 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $180.6 million, compared to $198.4 million for the same period in 2024. The reduction in losses is attributed to a significant decrease in operating expenses, which fell to $52.2 million from $69.4 million year-over-year, driven by lower research and development (R&D) and general administrative costs.

R&D expenses for the third quarter were $34.1 million, down from $42.3 million in the prior year, primarily due to reduced clinical trial expenses and manufacturing costs. General and administrative expenses also decreased to $18.4 million from $27.1 million, reflecting lower commercial preparation costs and stock-based compensation. The company has not generated any revenue to date, as its product candidates remain in various stages of clinical development.

In terms of strategic developments, Rocket Pharmaceuticals underwent a corporate reorganization in July 2025, which included a workforce reduction of approximately 30%. This restructuring aims to streamline operations and focus resources on its AAV-based gene therapy platform targeting cardiovascular diseases. The company anticipates that these changes will reduce operating expenses by nearly 25% over the next year. Additionally, Rocket has received FDA clearance to resume its Phase 2 pivotal study of RP-A501 for Danon disease after addressing safety concerns that led to a temporary clinical hold.

As of September 30, 2025, Rocket Pharmaceuticals reported total assets of $368.0 million, down from $527.7 million at the end of 2024. The company had cash, cash equivalents, and investments totaling $222.8 million, which it believes will be sufficient to fund operations into the second quarter of 2027. The company continues to face significant risks, including the need for additional financing to support ongoing R&D efforts and the uncertainty surrounding the regulatory approval of its product candidates.

Looking ahead, Rocket Pharmaceuticals remains focused on advancing its gene therapy programs, particularly in the cardiovascular space, while exploring potential partnerships to enhance its development capabilities. The company is also evaluating the impact of recent changes in U.S. tax law on its financial statements and operations.